Solid Tumor
Conditions
Brief summary
Angiotensin-converting enzyme 2 (ACE2) plays an important role in renin-angiotensin system (RAS) and has been reported to relate with cancer. Recently, it has also been proved as the key target for COVID-19 infection. DX600 is a polypeptide that can specific binding to ACE2 specifically with nanomolar affinity reported in literature. This study constrcuted a radio-tracer, DX600 Labeled by PET Radionuclide, to monitoring biodistribution ACE2 in human beings, evaluate the detection ability of radio-tracer in ACE2 over-expression tumors and dynamic changes of ACE2 expression under therapy.
Interventions
OTHER68Ga-DX600 PET/CT
DX600, labeled with 68Ga will be used as a molecular imaging tracer for PET/CT scanning
Sponsors
Peking University Cancer Hospital & Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 18-75 years old; both sex; * ECoG 0 or 1; * Patients that would undergo biopsy or surgical operation with high ACE2 expression tumors such as colorectal cancer, renal cancer, pancreatic cancer, gastric cancer, liver cancer, lung cancer, brain cancer or suspected tumor. * use 18F-FDG PET/CT as baseline evaluation
Exclusion criteria
* Significant hepatic or renal dysfunction; * Is Pregnant or ready to pregnant; * Cannot lie on their back for half an hour; * Suffering from claustrophobia or other mental diseases; * Refusal to join the clinical study;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SUV | 2 years | The uptake of uptake of the tracer in the primary and metastatic tumor lesions by measuring standardized uptake value（SUV） |
Countries
China
Outcome results
None listed